Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Pluristem Therapeutics Inc.    PSTI   US72940R1023

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/24/2015 02/25/2015 02/26/2015 02/27/2015 03/02/2015 Date
3.07(c) 3.07(c) 3.05(c) 3.04(c) 3.04 Last
111 678 119 663 42 597 72 070 63 678 Volume
+1.66% 0.00% -0.65% -0.33% 0.00% Change
More quotes
Company
Pluristem Therapeutics, Inc. is a bio-therapeutic company, which develops standardized cell therapy products for the treatment of life threatening diseases.The company's patented PLX (PLacental eXpanded) cells drug delivery platform releases a cocktail of therapeutic proteins in response to a... 
More about the company
Surperformance© ratings of Pluristem Therapeutics Inc
Trading Rating : - Investor Rating :
More Ratings
Chart PLURISTEM THERAPEUTICS INC
Duration : Period :
Pluristem Therapeutics Inc Technical Analysis Chart | PSTI | US72940R1023 | 4-Traders
Full-screen chart
Financials ($)
Sales 2015 0,52 M
EBIT 2015 -33,8 M
Net income 2015 -
Debt 2015 -
Yield 2015 -
Sales 2016 15,3 M
EBIT 2016 -26,9 M
Net income 2016 -24,1 M
Debt 2016 -
Yield 2016 -
PER 2015 -
PER 2016
Capi. / Sales 2015 409x
Capi. / Sales 2016 14,0x
Capitalization 214 M
More Financials
Latest news on PLURISTEM THERAPEUTICS INC
02/19 PLURISTEM THERAPEUTICS : Significant Findings in U.S. National Institutes of Hea..
02/18 PLURISTEM THERAPEUTICS : Significant Findings in U.S. National Institutes of Hea..
02/18 PLURISTEM THERAPEUTICS : Significant Findings in U.S. National Institutes of Hea..
02/11 PLURISTEM THERAPEUTICS : Announces Significant New Finding from Its Phase I/II M..
02/05 PLURISTEM THERAPEUTICS : Management's Discussion and Analysis of Financial Condi..
02/03 TUESDAY SECTOR LAGGARDS : Drugs, Biotechnology Stocks
02/02 MONDAY SECTOR LAGGARDS : Biotechnology, Airlines
02/02 Pluristem Announces Significant New Finding From Its Phase I/II Muscle Injury..
More news
Sector news Biotechnology & Medical Research - NEC
08:22a ACTELION : Selexipag (Uptravi) data in pulmonary arterial hypertension to be pre..
07:31a INCYTE : Appoints Steven H. Stein, MD as Chief Medical Officer
07:01a ISIS PHARMACEUTICALS : Earns $15 Million From GSK for Advancing ISIS-TTR Rx
Plus d'actualités du secteur Biotechnology & Medical Research - NEC


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF